Fig. 1

Patients with HNSCC with high TNFAIP2 expression tend to experience cisplatin treatment failure. (a) IHC staining for TNFAIP2 in the human HNSCC cohort. (b) TNFAIP2 protein expression in different T, N and clinical stages. (c) Kaplan‒Meier survival curve of HNSCC patients with low versus high TNFAIP2 expression. (d-f) Kaplan‒Meier survival curve of HNSCC patients with or without TPF chemotherapy in the whole group (d), high TNFAIP2 expression group (e) and low TNFAIP2 expression group (f). (g) IHC staining for TNFAIP2 in TPF chemotherapy-resistant and TPF chemotherapy-sensitive HNSCC patients. (h) Accuracy of TNFAIP2 level in predicting TPF chemotherapy response of HNSCC. (i-j) Correlation between TNFAIP2 mRNA expression and cisplatin IC50 in 10 HNSCC cell lines. (k-l) Cisplatin IC50 evaluations in TNFAIP2-overexpressing FADU (k) and CAL33 (l). (m) Xenograft images in nude mice after the indicated treatments. (n) Tumor growth curves of each group after the indicated treatments. (o) IHC staining for Ki67 in xenografts of each group. Scale bars, 100 μm. Data are presented as the mean ± SEM. n.s., not significant; *** P < 0.001. TPF, Taxol + platinum + fluorouracil; AUC, area under the curve; DMF, N, N-dimethylformamide; IOCV, tail vein injection